Acad Radiol

1. ZHANG X, Guo J, Yun Y, Shan D, et al
   Differentiation of Muscular Invasion in Bladder Cancer: Additional Value of Synthetic Magnetic Resonance Imaging.
   Acad Radiol. 2024 Mar 27:S1076-6332(24)00153-3. doi: 10.1016/j.acra.2024.
   

   >> Share

   
   

   
   Adv Mater

2. LI G, Wu S, Liu J, Wang K, et al
   Narrow Bandgap Schottky Heterojunction Sonosensitizer with High Electron-Hole Separation Boosted Sonodynamic Therapy in Bladder Cancer.
   Adv Mater. 2024 Mar 28:e2401252. doi: 10.1002/adma.202401252.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

3. XIE M, Zhou L, Li T, Lin Y, et al
   Targeting the KAT8/YEATS4 Axis Represses Tumor Growth and Increases Cisplatin Sensitivity in Bladder Cancer.
   Adv Sci (Weinh). 2024 Mar 25:e2310146. doi: 10.1002/advs.202310146.
   

   >> Share

   
   

   
   Aktuelle Urol

4. KLEBE M, Olbert PJ, Hofmann R, Barth PJ, et al
   [CpG-ODN instillation boosts ICAM-1 expression in an orthotopic murine UCC model: immunohistochemical evaluation of the local response to immunostimulatory DNA].
   Aktuelle Urol. 2024;55:154-160.
   

   >> Share

   
   
5. 
   [Not Available].
   Aktuelle Urol. 2024;55:100-102.
   

   >> Share

   
   

   
   Altern Ther Health Med

6. TAN H, Li Y, Li J, Wang K, et al
   The Mechanism of miR-29 in Bladder Cancer Released by Exosomes into Brain Microglia to Promote M2 Polarization and Angiogenesis in Brain Metastasis of Bladder Cancer.
   Altern Ther Health Med. 2024 Mar 22:AT10593.
   

   >> Share

   
   
7. CAO M, Cao Y, Xue S, Zhang Q, et al
   Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
   Altern Ther Health Med. 2024 Mar 22:AT10582.
   

   >> Share

   
   

   
   Anticancer Res

8. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
   Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
   Anticancer Res. 2024;44:1417-1423.
   

   >> Share

   
   
9. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
   Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
   Anticancer Res. 2024;44:1675-1681.
   

   >> Share

   
   

   
   Antioxidants (Basel)

10. DUGBARTEY GJ, Relouw S, McFarlane L, Sener A, et al
    Redox System and Oxidative Stress-Targeted Therapeutic Approaches in Bladder Cancer.
    Antioxidants (Basel). 2024;13:287.
    

    >> Share

    
    

    
    Asia Pac J Clin Oncol

11. KEALEY J, Ip C, Davis ID, Sengupta S, et al
    The impact of multidisciplinary cancer meetings in guiding treatment intent in patients with upper tract urothelial carcinoma.
    Asia Pac J Clin Oncol. 2024;20:41-45.
    

    >> Share

    
    

    
    Asian Pac J Cancer Prev

12. NANDANA PI, Rasyid H, Prihantono P, Yustisia I, et al
    Cytotoxicity and Apoptosis Studies of Brucein D against T24 Bladder Cancer Cells.
    Asian Pac J Cancer Prev. 2024;25:921-930.
    

    >> Share

    
    

    
    Biomater Res

13. WU S, Li G, Ouyang W, Tian Y, et al
    Ferrous Selenide Stabilized Black Phosphorus Heterojunction Sonosensitizer for MR Imaging-Guided Sonodynamic Therapy of Bladder Cancer.
    Biomater Res. 2024;28:0014.
    

    >> Share

    
    

    
    Biomed Res Int

14. INTERNATIONAL BR
    Retracted: lncRNA MIR4435-2HG Accelerates the Development of Bladder Cancer through Enhancing IQGAP3 and CDCA5 Expression.
    Biomed Res Int. 2024;2024:9783095.
    

    >> Share

    
    

    
    Biomedicines

15. PEREIRA M, Vale N
    Exploring Darunavir, Rilpivirine and Etravirine as Potential Therapies for Bladder Cancer: Efficacy and Synergistic Effects.
    Biomedicines. 2024;12:647.
    

    >> Share

    
    

    
    BMC Med Res Methodol

16. ROSS J, Lavallee LT, Hickling D, van Walraven C, et al
    Development of the multivariate administrative data cystectomy model and its impact on misclassification bias.
    BMC Med Res Methodol. 2024;24:73.
    

    >> Share

    
    

    
    BMC Urol

17. JIN P, Yang L, Liu Y, Huang J, et al
    Quantitative differentiation of non-invasive bladder urothelial carcinoma and inverted papilloma based on CT urography.
    BMC Urol. 2024;24:73.
    

    >> Share

    
    
18. TANG C, Fan Y, Zhu S
    Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
    BMC Urol. 2024;24:69.
    

    >> Share

    
    
19. HE Y, Pan C, Zhang Y, Lv M, et al
    Nomogram for customized recurrence prediction in primary non-muscle-invasive bladder cancer based on routine blood and urine parameters.
    BMC Urol. 2024;24:67.
    

    >> Share

    
    

    
    BMJ Case Rep

20. SMITH B, Khanna K, Pierce DP, Patel T, et al
    Chronic pelvic pain and dysmenorrhea disguising a rare submucosal leiomyoma of the urinary bladder.
    BMJ Case Rep. 2024;17:e258971.
    

    >> Share

    
    

    
    Cancer Biomark

21. LIU Y, Pang Z, Wang J, Wang J, et al
    Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer.
    Cancer Biomark. 2024 Jan 25. doi: 10.3233/CBM-230286.
    

    >> Share

    
    

    
    Cancers (Basel)

22. AL-MARSOUMMI S, Mehus AA, Garrett SH, Sens DA, et al
    The Effect of Retinoic Acid on Arsenite-Transformed Malignant UROtsa Bladder Cancer Cells: In Vitro Model of Basal Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2024;16:1178.
    

    >> Share

    
    
23. DUEX J, Theodorescu D
    CD44 in Bladder Cancer.
    Cancers (Basel). 2024;16:1195.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

24. LI D, Wu R, Wang J, Ye J, et al
    A Prognostic Index Derived From LASSO-Selected Preoperative Inflammation and Nutritional Markers for Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024 Feb 29:102061. doi: 10.1016/j.clgc.2024.
    

    >> Share

    
    

    
    Cureus

25. GERCEK O, Senkol M, Yazar VM, Topal K, et al
    The Effect of Lymphovascular Invasion on Short-Term Tumor Recurrence and Progression in Stage T1 Bladder Cancer.
    Cureus. 2024;16:e54844.
    

    >> Share

    
    

    
    Curr Issues Mol Biol

26. SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
    Prognostic Value of P63 Expression in Muscle-Invasive Bladder Cancer and Association with Molecular Subtypes-Preliminary Report.
    Curr Issues Mol Biol. 2024;46:2456-2467.
    

    >> Share

    
    

    
    Diabetes Metab Res Rev

27. LIN L, Ning K, Xiang L, Peng L, et al
    SGLT2 inhibition and three urological cancers: Up-to-date results.
    Diabetes Metab Res Rev. 2024;40:e3797.
    

    >> Share

    
    

    
    Discov Med

28. LIU FL, Zhang ZC, Zhou SL, Liu XL, et al
    Unlocking the Therapeutic Potential of LncRNA BLACAT1 in Hypopharynx Squamous Cell Carcinoma.
    Discov Med. 2024;36:546-558.
    

    >> Share

    
    

    
    Diseases

29. BARBOS V, Feciche B, Latcu S, Croitor A, et al
    The Assessment of SF-36 Survey for Quality-of-Life Measurement after Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Systematic Review.
    Diseases. 2024;12:56.
    

    >> Share

    
    

    
    Environ Int

30. JHUANG JR, Lee CH, Chiang CJ, Chen CJ, et al
    Reduced burden of Arsenic-Related cancers after water mitigation in Taiwan.
    Environ Int. 2024;185:108542.
    

    >> Share

    
    

    
    ESMO Open

31. DI GIACOMO AM, Schenker M, Medioni J, Mandziuk S, et al
    A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203).
    ESMO Open. 2024;9:102387.
    

    >> Share

    
    

    
    Eur Urol

32. DUQUESNE I, de la Taille A
    Re: Erdafitinib in BCG-treated High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2024 Mar 26:S0302-2838(24)02206-1. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    
33. ZHOU Y, D'Andrea VD, Shanmugam SP, Stelter I, et al
    Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer.
    Eur Urol. 2024 Mar 23:S0302-2838(24)02231-0. doi: 10.1016/j.eururo.2024.
    

    >> Share

    
    

    
    Eur Urol Oncol

34. TSUJI K, Kaneko M, Harada Y, Fujihara A, et al
    A Fully Automated Artificial Intelligence System to Assist Pathologists' Diagnosis to Predict Histologically High-grade Urothelial Carcinoma from Digitized Urine Cytology Slides Using Deep Learning.
    Eur Urol Oncol. 2024;7:258-265.
    

    >> Share

    
    

    
    Front Oncol

35. AUBERT C, Culty T, Zidane M, Bigot P, et al
    Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment.
    Front Oncol. 2024;13:1240378.
    

    >> Share

    
    

    
    Healthcare (Basel)

36. DA PRAT V, Aretano L, Moschini M, Bettiga A, et al
    Effectiveness of Preoperative Immunonutrition in Improving Surgical Outcomes after Radical Cystectomy for Bladder Cancer: Study Protocol for a Multicentre, Open-Label, Randomised Trial (INu-RC).
    Healthcare (Basel). 2024;12:696.
    

    >> Share

    
    

    
    Hum Cell

37. ZARZYCKA M, Kotula-Balak M, Gil D
    The mechanism of the contribution of ICAM-1 to epithelial-mesenchymal transition (EMT) in bladder cancer.
    Hum Cell. 2024 Mar 22. doi: 10.1007/s13577-024-01053.
    

    >> Share

    
    

    
    Hum Vaccin Immunother

38. LV Z, Hou J, Wang Y, Wang X, et al
    Reply to "Knowledge-map analysis and bladder cancer immunotherapy: Comment".
    Hum Vaccin Immunother. 2024;20:2325756.
    

    >> Share

    
    

    
    Insights Imaging

39. YANG G, Bai J, Hao M, Zhang L, et al
    Enhancing recurrence risk prediction for bladder cancer using multi-sequence MRI radiomics.
    Insights Imaging. 2024;15:88.
    

    >> Share

    
    

    
    Int J Mol Sci

40. SHIN J, Park JW, Kim SY, Lee JH, et al
    Strategies for Overcoming Immune Evasion in Bladder Cancer.
    Int J Mol Sci. 2024;25:3105.
    

    >> Share

    
    
41. PEREIRA F, Domingues MR, Vitorino R, Guerra IMS, et al
    Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.
    Int J Mol Sci. 2024;25:3347.
    

    >> Share

    
    
42. FERREIRA E, Ferreira D, Relvas-Santos M, Freitas R, et al
    Aberrantly Glycosylated GLUT1 as a Poor Prognosis Marker in Aggressive Bladder Cancer.
    Int J Mol Sci. 2024;25:3462.
    

    >> Share

    
    
43. VIKERFORS A, Davidsson S, Carlsson J, Jerlstrom T, et al
    Plasma Levels of Pentraxin 3: A Potential Prognostic Biomarker in Urinary Bladder Cancer Patients.
    Int J Mol Sci. 2024;25:3473.
    

    >> Share

    
    
44. KDIMATI S, Christoph C, Glass A, Engel N, et al
    Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
    Int J Mol Sci. 2024;25:3492.
    

    >> Share

    
    

    
    Int Urol Nephrol

45. SILVA MEDEIROS M, Botelho de Carvalho LA, Alves M, Papoila A, et al
    Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Mar 26. doi: 10.1007/s11255-024-03971.
    

    >> Share

    
    

    
    Int Wound J

46. YANG F, Nie J, Xiao F, Liu J, et al
    Impacts of enhanced recovery after surgery nursing interventions on wound infection and complications following bladder cancer surgery: A meta-analysis.
    Int Wound J. 2024;21:e14781.
    

    >> Share

    
    

    
    Ir J Med Sci

47. CHEVARRIA J, Ebad CA, Hamill M, Constandache C, et al
    Long-term renal function following radical cystectomy and ileal conduit creation.
    Ir J Med Sci. 2024;193:639-644.
    

    >> Share

    
    

    
    J Cancer Res Clin Oncol

48. JIANG C, Li X, Chen R, Yang Y, et al
    Enzyme-labeled liquid-based cytology (ELLBC): a new noninvasive diagnostic method for bladder cancers.
    J Cancer Res Clin Oncol. 2024;150:169.
    

    >> Share

    
    

    
    J Cancer Surviv

49. SCHUBACH K, Niyonsenga T, Turner M, Paterson C, et al
    Identifying the supportive care needs of people affected by non-muscle invasive bladder cancer: An integrative systematic review.
    J Cancer Surviv. 2024 Mar 23. doi: 10.1007/s11764-024-01558.
    

    >> Share

    
    

    
    J Egypt Natl Canc Inst

50. REJEB SB, Elfekih S, Kouki N, Boulma R, et al
    Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer.
    J Egypt Natl Canc Inst. 2024;36:9.
    

    >> Share

    
    

    
    J Hazard Mater

51. SHI Y, Xia W, Liu H, Liu J, et al
    Trihalomethanes in global drinking water: Distributions, risk assessments, and attributable disease burden of bladder cancer.
    J Hazard Mater. 2024;469:133760.
    

    >> Share

    
    

    
    J Mater Sci Mater Med

52. WANG J, Yin Y, Ren X, Wang S, et al
    Electrospun nanofibrous mats loaded with gemcitabine and cisplatin suppress bladder tumor growth by improving the tumor immune microenvironment.
    J Mater Sci Mater Med. 2024;35:21.
    

    >> Share

    
    

    
    J Med Case Rep

53. YOGEETA F, Malik Z, Rauf SA, Devi M, et al
    Recurrent bladder leiomyoma: a case report.
    J Med Case Rep. 2024;18:173.
    

    >> Share

    
    

    
    J Med Econ

54. TEITSSON S, Brodtkorb TH, Kurt M, Patel MY, et al
    Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo.
    J Med Econ. 2024;27:473-481.
    

    >> Share

    
    

    
    J Transl Med

55. KONG T, Qu Y, Zhao T, Niu Z, et al
    Identification of novel protein biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity extension analysis.
    J Transl Med. 2024;22:314.
    

    >> Share

    
    

    
    J Wound Ostomy Continence Nurs

56. CHE X, Huang H, Wang W, Zhong L, et al
    Parastomal Hernia Following Ileal Conduit: Incidence, Risk Factors, and Health-Related Quality of Life.
    J Wound Ostomy Continence Nurs. 2024;51:126-131.
    

    >> Share

    
    

    
    Kaohsiung J Med Sci

57. 
    Retraction: 'ASPM predicts poor prognosis and regulates cell proliferation in bladder cancer'. Zhen-Ya Gao, Fang Yu, Huan-Xia Jia, Zhuo Ye, Shi-Jie Yao, Kaohsiung J Med Sci. 2020; 36: 1021-1029 (https://doi.org/10.1002/kjm2.12284).
    Kaohsiung J Med Sci. 2024 Mar 28. doi: 10.1002/kjm2.12825.
    

    >> Share

    
    
58. YANG XX, Wang C
    CircITGA7 regulates malignant phenotypes in bladder cancer cells via targeting miR-330-3p/KLF10 axis.
    Kaohsiung J Med Sci. 2024 Mar 25. doi: 10.1002/kjm2.12821.
    

    >> Share

    
    

    
    Medicina (Kaunas)

59. OTOSHI T, Yamasaki T, Matsue T, Yukimatsu N, et al
    Comparison of Oncological Outcomes between Transperitoneal and Retroperitoneal Approaches in Laparoscopic Nephroureterectomies for Upper Tract Urothelial Carcinoma.
    Medicina (Kaunas). 2024;60:421.
    

    >> Share

    
    

    
    Medicine (Baltimore)

60. DENG Y, Huang M, Deng R, Wang J, et al
    Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature.
    Medicine (Baltimore). 2024;103:e37562.
    

    >> Share

    
    
61. SALEH M, Raffoul P, Akil A, Bassil P, et al
    Arab world's impact on bladder cancer research and opportunities for growth: A bibliometric review study.
    Medicine (Baltimore). 2024;103:e37554.
    

    >> Share

    
    

    
    Mod Pathol

62. POSADA JM, Yakirevich E, Kamat AM, Sood A, et al
    Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
    Mod Pathol. 2024;37:100424.
    

    >> Share

    
    

    
    Nat Commun

63. GIL-JIMENEZ A, van Dijk N, Vos JL, Lubeck Y, et al
    Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.
    Nat Commun. 2024;15:2538.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

64. KATOH M, Loriot Y, Brandi G, Tavolari S, et al
    FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
    Nat Rev Clin Oncol. 2024;21:312-329.
    

    >> Share

    
    
65. ALIMOHAMED N, Sridhar SS
    Combination strategies for advanced-stage urothelial carcinoma: a paradigm shift.
    Nat Rev Clin Oncol. 2024;21:255-256.
    

    >> Share

    
    

    
    Nursing

66. PULLEN RL JR
    Bladder cancer: An Update.
    Nursing. 2024;54:27-39.
    

    >> Share

    
    
67. 
    Bladder cancer: An Update.
    Nursing. 2024;54:39-40.
    

    >> Share

    
    

    
    Photochem Photobiol

68. RAHMAN KMM, Kumbham S, Bist G, Woo S, et al
    Comparison of red and green light for treating non-muscle invasive bladder cancer in rats using singlet oxygen-cleavable prodrugs with PPIX-PDT.
    Photochem Photobiol. 2024 Mar 27. doi: 10.1111/php.13933.
    

    >> Share

    
    

    
    Phytomedicine

69. LI D, Wang J, Tuo Z, Yoo KH, et al
    Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential.
    Phytomedicine. 2024;127:155503.
    

    >> Share

    
    

    
    PLoS One

70. CHEN LC, Yang HJ, Yu BH, Lee MS, et al
    Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
    PLoS One. 2024;19:e0300391.
    

    >> Share

    
    

    
    Praxis (Bern 1994)

71. JOHN H
    [BCG instillation sepsis in bladder carcinoma].
    Praxis (Bern 1994). 2024;113:44.
    

    >> Share

    
    

    
    Rom J Morphol Embryol

72. ADELMANN TG, Ceausu AR, Gaje NP, Raica M, et al
    Endothelial cell proliferation and vascular patterns in urothelial carcinoma.
    Rom J Morphol Embryol. 2024;65:61-67.
    

    >> Share

    
    

    
    Sci Rep

73. LIM Y, Park J, Lim JE, Park M, et al
    Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy.
    Sci Rep. 2024;14:7390.
    

    >> Share

    
    

    
    Skin Res Technol

74. DU L, Wang B, Wen J, Zhang N, et al
    Examining the causal association between psoriasis and bladder cancer: A two-sample Mendelian randomization analysis.
    Skin Res Technol. 2024;30:e13663.
    

    >> Share

    
    

    
    Urol Oncol

75. NUIJENS ST, van Osch FHM, van Hoogstraten LMC, Witjes JA, et al
    Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes.
    Urol Oncol. 2024;42:117.
    

    >> Share

    
    
76. EGEN L, Wessels F, Quan A, Westhoff N, et al
    Maximizing efficiency and ensuring safety: Exploring the outcomes of 2 consecutive open radical cystectomies by the same team within a single surgical day.
    Urol Oncol. 2024;42:118.
    

    >> Share

    
    
77. GHOREIFI A, Shishido SN, Sayeed S, Courcoubetis G, et al
    Blood-based liquid biopsy: A promising noninvasive test in diagnosis, surveillance, and prognosis of patients with upper tract urothelial carcinoma.
    Urol Oncol. 2024;42:118.
    

    >> Share

    
    
78. STROTHER M, Barlotta R, Uzzo R, Bloom E, et al
    Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessment.
    Urol Oncol. 2024;42:117.
    

    >> Share

    
    

    
    Urologia

79. SINGH V, Sarangi SS, Bhirud DP, Sharma K, et al
    Assessing pentafecta outcomes post radical cystectomy: A tertiary care center study.
    Urologia. 2024;91:49-54.
    

    >> Share

    
    
80. TANDON M, Chakraborty S, Barkondaj B, Choudhury S, et al
    Role of multiparametric MRI in predicting muscle invasiveness in urinary bladder neoplasms with pathological correlations.
    Urologia. 2024;91:55-60.
    

    >> Share

    
    

    
    World J Urol

81. SHOJO K, Takeda T, Akita H, Suzuki T, et al
    Prediction of pathological up-staging after radical nephroureterectomy in patients with upper tract urothelial carcinoma.
    World J Urol. 2024;42:192.
    

    >> Share

    
    
82. URABE F, Tsuzuki S, Kimura T
    Letter to the editor for the article "Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma".
    World J Urol. 2024;42:198.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share